Advances in the study of peptide drugs in oral drug delivery system
10.16438/j.0513-4870.2021-1491
- VernacularTitle:肽类药物的口服递送研究进展
- Author:
Qi LI
;
Hong-da CHEN
;
Tian-hua ZHOU
;
Xiang-rui LIU
- Publication Type:Research Article
- Keywords:
peptide drug;
oral drug administration;
gastrointestinal absorption;
permeation enhancer;
patent medicine;
rug delivery system
- From:
Acta Pharmaceutica Sinica
2022;57(7):2012-2023
- CountryChina
- Language:Chinese
-
Abstract:
Peptide drugs exhibit an irreplaceable role in clinics due to their high specificity, efficiency and low toxicity. At present, more than 80 peptide drugs have been approved for marketing with global sales exceeding $50 billion in 2019. However, with large molecular weights, high hydrophilicity and instability in digestive tract, oral peptide drugs encounter substantial physiological barriers leading to low oral bioavailability. Therefore, peptide drugs are mostly administered by parenteral routes. Although parenteral delivery of peptide drugs achieves high bioavailability, this is associated with inconvenience and discomfort, even causing severe side effects compared with the oral route possessing a high degree of patient compliance. Therefore, numerous studies concentrate on novel strategies to improve the oral bioavailability of peptide drugs. Some delivery technologies such as Eligen™ and Axcess™ have been successfully applied to the oral dosage form of therapeutic peptides and have accelerated relevant oral formulations for Food and Drug Administration (FDA) approval and clinical treatment. In this review, we focus on the oral peptide delivery, mainly summarizing the progress of recent strategies used to overcome oral barriers and the commercialization applications of related patents, which could facilitate the research and development (R&D) of clinical applications of oral delivery techniques for peptide drugs.
